Last reviewed · How we verify

Formulation C: OnabotulinumtoxinA — Competitive Intelligence Brief

Formulation C: OnabotulinumtoxinA (Formulation C: OnabotulinumtoxinA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology.

phase 2 Botulinum toxin Acetylcholine release Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Formulation C: OnabotulinumtoxinA (Formulation C: OnabotulinumtoxinA) — Allergan. OnabotulinumtoxinA works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Formulation C: OnabotulinumtoxinA TARGET Formulation C: OnabotulinumtoxinA Allergan phase 2 Botulinum toxin Acetylcholine release
Magnesium Sulfate Magnesium Sulfate Pfizer marketed Electrolyte; anticonvulsant Neuromuscular junction; motor nerve impulse; acetylcholine release 1981-01-01
Intradetrusor Botox Injections Intradetrusor Botox Injections The Methodist Hospital Research Institute marketed Neurotoxin; botulinum toxin type A SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
Botulinum Toxin A (Botox ) Botulinum Toxin A (Botox ) Assistance Publique - Hôpitaux de Paris marketed Neurotoxin; acetylcholine release inhibitor SNARE proteins (specifically SNAP-25); acetylcholine release machinery
botulinum type a botulinum type a Henry Ford Health System marketed Neurotoxin; botulinum toxin SNARE proteins (synaptobrevin, SNAP-25, syntaxin); acetylcholine release machinery
PrabotulinumtoxinA-Xvfs PrabotulinumtoxinA-Xvfs Lupo Center for Aesthetic and General Dermatology marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)
Xeomin® Xeomin® ATGC Co., Ltd. marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery at neuromuscular junction)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

  1. Galderma R&D · 2 drugs in this class
  2. Hexsel Dermatology Clinic · 2 drugs in this class
  3. Seoul National University Hospital · 2 drugs in this class
  4. University of Utah · 2 drugs in this class
  5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
  6. EuBiologics Co.,Ltd · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Beth Israel Deaconess Medical Center · 1 drug in this class
  10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Formulation C: OnabotulinumtoxinA — Competitive Intelligence Brief. https://druglandscape.com/ci/formulation-c-onabotulinumtoxina. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: